Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
09 janv. 2022 12h00 HE
|
Exagen Inc.
SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a...
Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
17 nov. 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33rd Annual Virtual...
Exagen Inc. Reports Third Quarter 2021 Results
10 nov. 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021....
Exagen Inc. to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum
04 nov. 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity Virtual...
Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021
27 oct. 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021...
Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus
27 oct. 2021 08h25 HE
|
Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered...
Exagen Inc. Announces $27.2 Million Debt Refinancing
25 oct. 2021 08h25 HE
|
Exagen Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security...
Exagen Showcases Eight Scientific Presentations at ACR’s Virtual Annual Meeting in November 2021
21 oct. 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the...
Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
13 sept. 2021 16h15 HE
|
Exagen Inc.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global...
Exagen Inc. Reports Second Quarter 2021 Results
09 août 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2021. ...